Navigation Links
S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
Date:9/17/2008

SINGAPORE, Sept. 18 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma. These first Phase I trials for SB1518 comprise of ascending dose studies conducted at several leading clinical sites in the United States. The trials are expected to enroll up to 60 patients and are designed to determine the maximum tolerated dose and to assess the pharmacokinetics and overall safety profile of SB1518.

SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild-type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in various myeloproliferative disorders such as idiopathic myelofibrosis. SB1518 might also provide an effective treatment for other hematological malignancies with mutations and re-arrangements in the JAK2 gene.

"The entry of SB1518 into the clinical phase marks an important milestone for S*BIO and potentially offers a new targeted therapy for this group of difficult-to-treat patients that represent a significant unmet medical need," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "SB1518 has demonstrated exciting anti-proliferative and anti-tumor activity, combined with excellent tolerability in relevant in vitro and in vivo models. We are pleased to conduct our company's first clinical trials in the United States at well respected centers such as The University of Texas M.D. Anderson Cancer Center, the University of Chicago Medical Center and the Fred Hutchinson Cancer Research Center."

In addition to SB1518, S*BIO has a robust pipeline including SB939, the company's lead histone deacetylase (HDAC) inhibitor, which is currently in Phase I trials in Singapore and Canada. S*BIO's target-driven approach to developing innovative small molecule therapies for cancer is built on a profound unde
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
3. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
4. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
5. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
6. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
7. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
8. Isis Initiates Clinical Trial of CRP Drug
9. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
10. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009).... 3 ParagonRx, a Delaware-based co...nt and optimal medication use, will host a free we...dance on REMS - Risk Evaluation Mitigation Strateg...le management. Dr. Gary Slatko, chief medical off...anagement programs, will lead the one-hour program...
(Date:12/3/2009)..., Dec. 3 Wound Manag...), a rapidly growing provider of specialty medical...ealth Industry Representative Association (HIRA) t...arketing representative to market the company,s co..., HIRA will market and sell Wound Management Tec...
(Date:12/3/2009)...3 TROY Group, Inc., a Worldwide L...ounces the addition of the TROY 3015 SecureRx(TM) ...g solutions. Based on the HP LaserJet Enterprise P...ters provide a fast 42 page per minute print speed... and enhanced TROY prescription security features....
Breaking Medicine Technology:Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3New TROY SecureRx Prescription Printer Marks 50th Hospital Installation Milestone 2SemBioSys securityholder vote to be held December 18 2009 with a record date of November 16 2009 14878 1SemBioSys securityholder vote to be held December 18 2009 with a record date of November 16 2009 14878 2SemBioSys securityholder vote to be held December 18 2009 with a record date of November 16 2009 14878 3VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results 6356 1VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results 6356 2Cancer patients and doctors report drug side effects differently 61571 1Cancer patients and doctors report drug side effects differently 61571 2
(Date:12/4/2009)... The renowned Center for mind-body medi...g the only natural immuno-boosting herbal suppleme...rveda. , San Diego, Calif...nprecedented illness due to factors such as stress... millions of people around the world are looking f...
(Date:12/3/2009)... With a membership increase of more tha...ement not only as a milestone in its history, but ...ce. Most associations are experiencing a decline i...o;At a time when trade organizations across the na...experiencing unprecedented growth, signaling that ...
(Date:12/3/2009)...INNEAPOLIS, Dec. 3 Children,s Hosp...cipient of the 2009 Leapfrog Top Hospitals Award. ...ering care that is among the best in the nation wh...y. ,, The Leapfrog survey is the only national,...uding mortality rates for common procedures, infec...
(Date:12/3/2009)...EVERLY HILLS, Calif., Dec. 3 Chris...ivine Design Gala and Premier Shopping Event for P...at 50-70% off regular prices. The event kicks off...December 7, 2009, located at 9900 Wilshire Bouleva...rnia. Please visit www.divinedesign.org for mor...
(Date:12/3/2009)...erforms widely used sulfonylureas, but each patien...RSDAY, Dec. 3 (HealthDay News) -- A class of drug...abetes is associated with a higher risk of dying a...n, researchers say. , , Sulfonylureas, long a m... than metformin in a study of oral anti-diabetes d...
Breaking Medicine News(10 mins):Health News:The Chopra Center for Wellbeing Launches Vedamune: An Ayurvedic Supplement to Support The Immune System 2Health News:Florida Medical Association Marks Record Membership Growth 2Health News:Children's Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 2Health News:Christian Audigier Represented at Divine Design for Project Angel Food 2Health News:Diabetes Drugs Go Head-to-Head in Study 2Health News:Diabetes Drugs Go Head-to-Head in Study 3
...are Realty,Trust Incorporated (NYSE: HR ) today a... 31, 2008. Revenues for the first quarter of 2008 ...r,s $52.6 million. Income from,continuing operatio...d a $30.4 million gain,related to the disposal of ...
... phobia, study finds , , MONDAY, May 5 (He...ions about their children,s fever and overtreat mi...shows. , Parents, ethnicity may also play a role i...ix it, so every pediatrician must have the fever t...
...s are ,doing fine, researcher says , , MON...of adopted American teens appear to be at heighten...blems than their non-adopted counterparts. , But t...doing fine," said Margaret Keyes, lead author of t...
...the Center for Translational Medicine at Thomas Je... a protein that appears to have protective and per... a similar role in high blood pressure. They found... led by Patrick Most, M.D., assistant professor of...
... Scientific Conference, SALEM, Ore., May 5 The N...ill present the Fibromyalgia and Sleep Disorders,s..., Oregon at the Portland,Marriott Downtown Waterfr...bromyalgia and related illnesses. This meeting, or...
...vestments, Inc. is,pleased to announce the acquisi...or the "Company"), owner and operator of The Medic... in the Philippines. Its facilities,include a 500 ...als,led by Alfredo R.A. Bengzon, a former Secretar...
Other Medicine News:Health News:Healthcare Realty Trust Announces First Quarter Results 2Health News:Healthcare Realty Trust Announces First Quarter Results 3Health News:Healthcare Realty Trust Announces First Quarter Results 4Health News:Healthcare Realty Trust Announces First Quarter Results 5Health News:Healthcare Realty Trust Announces First Quarter Results 6Health News:Healthcare Realty Trust Announces First Quarter Results 7Health News:Healthcare Realty Trust Announces First Quarter Results 8Health News:Ethnicity Plays Role in Parents' Treatment of Childhood Fever 2Health News:Adopted Children at Slightly Higher Mental Health Risk 2Health News:Adopted Children at Slightly Higher Mental Health Risk 3Health News:Double duty: Loss of protective heart failure protein causes high blood pressure 2Health News:Double duty: Loss of protective heart failure protein causes high blood pressure 3Health News:Exploring the Frontiers of Neuroscience 2Health News:Exploring the Frontiers of Neuroscience 3Health News:Lombard Makes Investment in The Medical City, a Leading Philippine Hospital and Healthcare Provider 2
...ee™ is a 1-step, hand-held, point-of-care de... metabolites in human urine. The TOX/See device c...rugs in 3 to 8 minutes and requires only a few dro... packaged to maximize convenience and ease of use....
Sugar-Chex Linearity Glucose Control
Streck Cytometry Sheath Fluid
Cyto-Chex Storage and Transport Solution
Medicine Products: